Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Safety Profile of Atrial Fibrillation Ablation Using a Second-Generation Cryoballoon in Japan: Insight From a Large Multicenter Observational Study.
Miyazaki S, Kobori A, Sasaki Y, Miyamoto K, Sato E, Hanazawa K, Morishima I, Kanzaki Y, Yamaji H, Yamao K, Kondo Y, Watanuki M, Kaneshiro T, Uchiyama T, Nakamura K, Hiramatsu S, Nakajima J, Arimoto T, Kaneko S, Osai N, Takagi T, Kaseno K, Takahashi A, Naito S, Kobayashi Y, Hachiya H, Kusano K, Yagi T, Iesaka Y, Tada H. Miyazaki S, et al. Among authors: osai n. JACC Clin Electrophysiol. 2021 May;7(5):604-613. doi: 10.1016/j.jacep.2020.11.016. Epub 2021 Feb 24. JACC Clin Electrophysiol. 2021. PMID: 33640351 Free article.
A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy.
Horie K, Matsumoto T, Mizutani Y, Tada N, Osai N, Isawa T, Taguri M, Kato S, Honda T, Ootomo T, Inoue N. Horie K, et al. Among authors: osai n. Cardiovasc Interv Ther. 2020 Apr;35(2):150-161. doi: 10.1007/s12928-019-00589-7. Epub 2019 May 15. Cardiovasc Interv Ther. 2020. PMID: 31093885
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.